Introduction: The role of platelets (Ps) and platelet-derived microparticles (MPs) in venous thromboembolism (VTE) is still being debated. Methods: We measured MPs, velocity of thrombin formation (PiCT) and phospholipid generation (PLPs) in 40 patients with unprovoked deep vein thrombosis (DVT), who were compared with 40 healthy controls. Results: MPs were higher in DVT (7.12 nM; 25th–75th percentile 5.26–9.12) than in controls (5.45 nM; 25th–75th percentile 1.67–8.96) (p = 0.19). PiCT velocity was lower in DVT (1.87 sec; 25th–75th percentile 1.75–1.93 sec) compared with controls (1.95 sec; 25th– 75th percentile 1.84–2.24 sec) (p = 0.04). PLPs were higher in DVT (77.03 µg/mL; 25th– 75th percentile 72.12–103.59 µg/mL) compared with controls (68.65 µg/mL, 25th–75th percentile 55.31–78.20 µg/mL) (p = 0.02). Discussion: We hypothesize that MPs could be integrated with the lab network assay in evaluating Ps’ role as an activated procoagulative condition. We encourage research on Ps and P-derived microvesicle pathways in patients with unprovoked DVT and not only in patients with cancer-induced DVT.

Platelet-Derived Microparticles (MPs) and Thrombin Generation Velocity in Deep Vein Thrombosis (DVT): Results of a Case–Control Study

Pietro Zuccarello;
2020-01-01

Abstract

Introduction: The role of platelets (Ps) and platelet-derived microparticles (MPs) in venous thromboembolism (VTE) is still being debated. Methods: We measured MPs, velocity of thrombin formation (PiCT) and phospholipid generation (PLPs) in 40 patients with unprovoked deep vein thrombosis (DVT), who were compared with 40 healthy controls. Results: MPs were higher in DVT (7.12 nM; 25th–75th percentile 5.26–9.12) than in controls (5.45 nM; 25th–75th percentile 1.67–8.96) (p = 0.19). PiCT velocity was lower in DVT (1.87 sec; 25th–75th percentile 1.75–1.93 sec) compared with controls (1.95 sec; 25th– 75th percentile 1.84–2.24 sec) (p = 0.04). PLPs were higher in DVT (77.03 µg/mL; 25th– 75th percentile 72.12–103.59 µg/mL) compared with controls (68.65 µg/mL, 25th–75th percentile 55.31–78.20 µg/mL) (p = 0.02). Discussion: We hypothesize that MPs could be integrated with the lab network assay in evaluating Ps’ role as an activated procoagulative condition. We encourage research on Ps and P-derived microvesicle pathways in patients with unprovoked DVT and not only in patients with cancer-induced DVT.
2020
deep vein thrombosis
microparticles
platelet
extracellular vesicles
biomarkers
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12607/54114
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
social impact